FAMILIAL CHRONIC MYELOCYTIC LEUKEMIA: THE OCCURRENCE IN FIRST COUSINS IN JOS, NORTH CENTRAL NIGERIA
Keywords:
Myelocytic Leukemia, Familial chronic, Nigeria, Cousins
Abstract
Introduction: Chronic myeloid leukemia is a leukemic myeloproliferative disorder that is rarely diagnosed in members of the same family.
Aim: We report the occurrence of chronic myeloid leukemia in male first cousins in Jos.
Cases report: Two cousins 37 years and 31 years old were referred to our department for leucocytosis in the first patient and priapism and leucocytosis in the second. Full blood count and bone marrow aspiration cytology in both cases revealed granulocytic leucocytosis with all the stages of myeloid maturation in peripheral blood and marrow myeloid hyperplasia in keeping with chronic myeloid leukemia. Treatment with tyrosine kinase inhibitor (TKI) was delayed in both, due to financial constraints for transportation to the treatment center in Nigeria. Cytoreduction with hydroxyurea was the initial treatment instituted. Even with the eventual commencement of imatinib mesylate, the outcome was still poor in the second patient who transformed and died within one year.
Conclusion: Chronic myeloid leukemia has occurred in family members in our environment.
Downloads
Download data is not yet available.
References
1. Catovsky D, Hoffbrand AV. Acute leukemia. In: Hoffbrand AV, Lewis SM, Tuddenham EGD (edds). Postgraduate Haematology (4th edition), London, Arnold. 2001: p373-404.
2. Lichtman MA, Lesveld JL. Chronic myelogenous leukemia and related disorders. In: Ernest B, Marshall AL, Barry SC, Thomas JK, Uri S. Editors. Williams Haematology. 6th edd, McGraw Hill, Newyork, USA. 2001: 1085-1123.
3. Cervantes F, Ribera JM, Sanchez-Basono J, Brugues R, Rozman C. Myeloproliferative disorders in two young siblings. Cancer. 1984; 54: 899-902.
4. Takohata GK, Neely CL, Williams DL. Chronic myelocytic leukemia in identical twins and a sibling. Blood. 1968; 31: 216- 225.
5. Lardi AA, Taha OMA, al-Jefri A, Ahmed MAM. Familial chronic myelocytic leukemia-like syndrome probably of congenital origin. Acta Paediatrica. 1994; 83: 558-560.
6. Oyekunle AA, Bolarinwa RA, Oyelese AT, Salawu L, Durosinmi MA. Determinants of overall and progression-free survival of Nigerian patients with Philadelphiapositive chronic myeloid leukemia. Adv Hematol. 2015; 2015: 908708. doi: 10.1155/2015/908708
7. Bjorkholm M, Kristinson SY, Landgren O, Golden LR. No familial aggregation in chronic myeloid leukemia. Blood. 2013; 122: 460-461.
8. Caocci G, Atzeni S, Vacca A, Orru N, Ledah A,La-Nasa G. Familial occurrence of chronic myeloid leukaemia. Leukaemia lymphoma. 2009; 80: 854-856.
9. Sawyer CL. Chronic myeloid leukemia. The New Engl J Med. 1999; 340: 1330- 1340.
10. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral center over 16 year period. Br J Haematol. 1977; 96: 111-116.
11. Burnett AL, Bivalacqua TJ. Priapism: Current principles and practice. Urologic Clinic of North America 34; 2007: 631- 642.
12. Bertram RA, Wedster GD, Carson CC. Priapism: Etiology, treatment, and results in a series of 35 presentations. Urology. 26; 1985: 229-232.
13. Akay OM, Mutlu F, Gulbas Z. Platelet dysfunction in patients with chronic myeloid leukemia: Does imatinib mesylate improve it? Turk J Haematol, 2016; 33:
127-130.
14. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. The N Engl J Med. 1999; 341:164–172.
15. Thompson PA, Kantarjian H, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. May Clin Proc. 2015; 90: 1140-1154.
16. Barbui T, Thiele J, Gisslinger H, et al. 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth
discussion. Blood Cancer J. 2018; 8(2):15. Published 2018 Feb 9. doi:10.1038/s41408-018-0054-y
17. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ et al. imatinib compared with Interferon and low dose cytarabine forDapus D. O. et al., Med. Res. Chronicles., 6(3), 110-116 2019 newly diagnosed chronic phase chronic myeloid leukemia. The New Engl J Med. 2003; 348: 994-1004.
18. Baccarani M, Pileri S, Steegmann JL, Midler M, Sovirini S, Drying M. Chronic myeloid leukemia. ESMO clinical and practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2012; 23 s7: 72-77.
19. Van-Etten RA, Larson RA, Rosmarin HG. Clinical manifestation and diagnosis of chronic myeloid leukemia. Available at: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronicmyeloid-leukaemia. Access on: 18th February 2019.
20. Trends in the pattern of leukemia incidence in Nigeria. Available at: www.bionline.org.bs/request?jm06019.Accessed on 18th February 2019.
21. Oyekunle AA, Durosinmi MA, Bolarinwa RA, owajuyigbe T,Salawu L, Akinola NO. Chronic myeloid leukemia in Nigeria: Anaemia is an independent predictor of
overall survival. Clin Med Insights Blood Disord. 2016; 9: 9-13.
22. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase chronic myeloid leukemia. Blood. 2012; 120: 1390-1397
23. Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. The oncologist. 2004; 9: 259-270. Baccarani M, Castagnetti F, Gugliotta G,
Palandri F, Rosti G. Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis. 2014; 6: e2014005. doi:10.4084MJHID2014.005
2. Lichtman MA, Lesveld JL. Chronic myelogenous leukemia and related disorders. In: Ernest B, Marshall AL, Barry SC, Thomas JK, Uri S. Editors. Williams Haematology. 6th edd, McGraw Hill, Newyork, USA. 2001: 1085-1123.
3. Cervantes F, Ribera JM, Sanchez-Basono J, Brugues R, Rozman C. Myeloproliferative disorders in two young siblings. Cancer. 1984; 54: 899-902.
4. Takohata GK, Neely CL, Williams DL. Chronic myelocytic leukemia in identical twins and a sibling. Blood. 1968; 31: 216- 225.
5. Lardi AA, Taha OMA, al-Jefri A, Ahmed MAM. Familial chronic myelocytic leukemia-like syndrome probably of congenital origin. Acta Paediatrica. 1994; 83: 558-560.
6. Oyekunle AA, Bolarinwa RA, Oyelese AT, Salawu L, Durosinmi MA. Determinants of overall and progression-free survival of Nigerian patients with Philadelphiapositive chronic myeloid leukemia. Adv Hematol. 2015; 2015: 908708. doi: 10.1155/2015/908708
7. Bjorkholm M, Kristinson SY, Landgren O, Golden LR. No familial aggregation in chronic myeloid leukemia. Blood. 2013; 122: 460-461.
8. Caocci G, Atzeni S, Vacca A, Orru N, Ledah A,La-Nasa G. Familial occurrence of chronic myeloid leukaemia. Leukaemia lymphoma. 2009; 80: 854-856.
9. Sawyer CL. Chronic myeloid leukemia. The New Engl J Med. 1999; 340: 1330- 1340.
10. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral center over 16 year period. Br J Haematol. 1977; 96: 111-116.
11. Burnett AL, Bivalacqua TJ. Priapism: Current principles and practice. Urologic Clinic of North America 34; 2007: 631- 642.
12. Bertram RA, Wedster GD, Carson CC. Priapism: Etiology, treatment, and results in a series of 35 presentations. Urology. 26; 1985: 229-232.
13. Akay OM, Mutlu F, Gulbas Z. Platelet dysfunction in patients with chronic myeloid leukemia: Does imatinib mesylate improve it? Turk J Haematol, 2016; 33:
127-130.
14. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. The N Engl J Med. 1999; 341:164–172.
15. Thompson PA, Kantarjian H, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. May Clin Proc. 2015; 90: 1140-1154.
16. Barbui T, Thiele J, Gisslinger H, et al. 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth
discussion. Blood Cancer J. 2018; 8(2):15. Published 2018 Feb 9. doi:10.1038/s41408-018-0054-y
17. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ et al. imatinib compared with Interferon and low dose cytarabine forDapus D. O. et al., Med. Res. Chronicles., 6(3), 110-116 2019 newly diagnosed chronic phase chronic myeloid leukemia. The New Engl J Med. 2003; 348: 994-1004.
18. Baccarani M, Pileri S, Steegmann JL, Midler M, Sovirini S, Drying M. Chronic myeloid leukemia. ESMO clinical and practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2012; 23 s7: 72-77.
19. Van-Etten RA, Larson RA, Rosmarin HG. Clinical manifestation and diagnosis of chronic myeloid leukemia. Available at: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-chronicmyeloid-leukaemia. Access on: 18th February 2019.
20. Trends in the pattern of leukemia incidence in Nigeria. Available at: www.bionline.org.bs/request?jm06019.Accessed on 18th February 2019.
21. Oyekunle AA, Durosinmi MA, Bolarinwa RA, owajuyigbe T,Salawu L, Akinola NO. Chronic myeloid leukemia in Nigeria: Anaemia is an independent predictor of
overall survival. Clin Med Insights Blood Disord. 2016; 9: 9-13.
22. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase chronic myeloid leukemia. Blood. 2012; 120: 1390-1397
23. Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. The oncologist. 2004; 9: 259-270. Baccarani M, Castagnetti F, Gugliotta G,
Palandri F, Rosti G. Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis. 2014; 6: e2014005. doi:10.4084MJHID2014.005
How to Cite
1.
Dr. Damulak Obadiah Dapus, Dr. Jatau Ezra Danjumma, Dr. Zakari Ayuba, Dr. Egesie J Ochaka. FAMILIAL CHRONIC MYELOCYTIC LEUKEMIA: THE OCCURRENCE IN FIRST COUSINS IN JOS, NORTH CENTRAL NIGERIA. Med. res. chronicles [Internet]. 2019Jun.30 [cited 2024Dec.26];6(3):110-6. Available from: https://medrech.com/index.php/medrech/article/view/378
Section
Original Research Article
